Insilico's AI-Driven Drug Shows Potential for Biological Age…

Event summary

Insilico's AI-designed drug rentosertib showed potential for biological age reversal in a Phase IIa trial for idiopathic pulmonary fibrosis (IPF), as assessed by six proteomic aging clocks.
The study, published in Nature Biotechnology, is the first clinical evaluation of an AI-discovered and designed drug candidate targeting both aging and disease biology.
Rentosertib demonstrated a dose-dependent reversal in predicted biological age and improvement in lung function (FVC) compared to placebo.
Insilico reported total revenue of approximately $106 million in the first half of 2026, a 287% year-over-year increase, and achieved its first profitable half-year since listing.
Rentosertib has advanced to a Phase III trial evaluating for idiopathic pulmonary fibrosis (IPF).

The big picture

Insilico's success with rentosertib represents a significant milestone in AI-driven drug discovery, demonstrating the potential to accelerate the development of geroprotective therapeutics. The company's ability to integrate aging biomarkers into disease-focused trials could reshape the landscape for longevity interventions, addressing a massive unmet need in the aging population. Insilico's profitability and growing pipeline productivity underscore the commercial viability of its AI-powered approach, positioning it as a leader in the convergence of biotechnology and artificial intelligence.

What we're watching

Clinical Validation: Whether rentosertib's age-reversal effects can be replicated in larger Phase III trials and in healthy volunteers, as suggested by Nobel laureate Michael Levitt.
Regulatory Pathways: The pace at which Insilico can qualify aging biomarkers under the FDA Biomarker Qualification Program and integrate them into standard clinical trials.
Commercial Viability: How Insilico's dual-purpose therapeutic strategy will scale across its 40+ drug programs and sustain its recent profitability.